For in vivo infection, an AAV with Mfsd2a knockdown (2 μl, 1.7*1012 viral genomes/mL) or a control virus (2 μl, 1.3*1012 viral genomes/mL) was administered via intracerebroventricular injection. This evidence concerns the gene MFSD2A and infection.